---
schema_version: "secwatch.filing_event.v1"
accession: "0001568276-22-000302"
form_type: "8-K"
ticker: "TENX"
cik: "0000034956"
company_name: "TENAX THERAPEUTICS, INC."
filed_at: "2022-01-31T23:59:59+00:00"
generated_at: "2026-06-27T13:47:08.949244+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Tenax Therapeutics appoints Robyn Hunter to Board, cures Nasdaq audit committee compliance

## Summary
- Robyn Hunter appointed as independent director and chair of Audit and Compliance Committee, effective Jan 28, 2022.
- Hunter is CFO of Fortress Biotech; adds financial and life sciences expertise to the Board.
- Appointment resolves non-compliance with Nasdaq Listing Rule 5605(c)(2)(A) for audit committee composition.
- Board remains majority independent following her appointment.

## SEC filing metadata
- accession: 0001568276-22-000302
- form_type: 8-K
- ticker: TENX
- cik: 0000034956
- company_name: TENAX THERAPEUTICS, INC.
- filed_at: 2022-01-31T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/34956/000156827622000302/0001568276-22-000302-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/34956/000156827622000302/tenx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001568276-22-000302
- JSON: https://secwatch.observer/filing/0001568276-22-000302.json
- Plain text: https://secwatch.observer/filing/0001568276-22-000302.txt

## Key facts
- Executive change
  Robyn M. Hunter was appointed as Member of the Board at TENAX THERAPEUTICS, INC..
  - Action: appointed
  - Role: Member of the Board
  source text: On January 26, 2022, the Board of Directors (the “Board”) of Tenax Therapeutics, Inc. (the “Company”) appointed Robyn M. Hunter as a member of the Board, effective January 28, 2022, to serve until the Company’s 2022 annual meeting of stockholders or until her successor is duly elected and qualified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/34956/000156827622000302/0001568276-22-000302-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.